An inhaled corticosteroid used as a controller medication for persistent asthma. Available as a dry powder inhaler (Flexhaler) for older children and adults, and as a nebulizer suspension (Respules) for infants and young children. Budesonide has a favorable safety profile, including the most extensive safety data in pregnancy among all inhaled corticosteroids. Also available as an oral formulation (Entocort) for inflammatory bowel disease and as a nasal spray (Rhinocort) for allergic rhinitis.
Reduces asthma exacerbations and improves lung function3,6
Once- or twice-daily dosing
What to watch for
Oral candidiasis (thrush)
Dysphonia (hoarseness)
Cough and throat irritation
Known hypersensitivity to budesonide or any component1,2
Primary treatment of acute asthma attacks or status asthmaticus2,3
The bottom line
Evidence rating strong. Most-documented uses: controller therapy for persistent asthma (adults and children >=6 months), nebulized form for infants and young children unable to use inhalers, most pregnancy safety data of any ics. 10 sources indexed (2004–2024), with 2 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Binds to the intracellular glucocorticoid receptor and modulates inflammatory gene transcription. The activated receptor complex suppresses NF-kB and AP-1 transcription factors, reducing the production of pro-inflammatory cytokines, chemokines, and adhesion molecules. Budesonide undergoes high first-pass hepatic metabolism (~90%), resulting in low systemic bioavailability from the swallowed portion. Its high receptor affinity and lipophilic ester conjugation in airway tissue provide prolonged local anti-inflammatory effect.
Class
Inhaled Corticosteroid
Absorption
Fat-soluble; take with food
Dosing
Dosing & protocol.
Common range
Flexhaler: 180-360 mcg BID (adults); Respules: 0.25-1 mg via nebulizer BID (children 12 months-8 years); titrate to lowest effective dose (as prescribed by your physician)
Recommended form
Dry powder inhaler (DPI) or nebulizer suspension
Delivered by inhalation directly to the airways. Systemic bioavailability approximately 6-13% (Flexhaler) or 6% (Respules) due to high first-pass metabolism. Rinse mouth after use to prevent oral candidiasis. For nebulizer use, use a mouthpiece rather than face mask to reduce facial skin deposition.3
Depletions
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Calcium
Mild
Long-term or high-dose inhaled corticosteroid exposure can reduce bone formation and contribute to poorer calcium balance.
Replace CalciumMonitor Bone density trend + serum calcium when indicatedOnset Usually over months to years of high-dose therapy
Safety
Full safety detail.
Side effects
Oral candidiasis (thrush)
Dysphonia (hoarseness)
Cough and throat irritation
Headache
Nasopharyngitis
Adrenal suppression (with high-dose chronic use)
Growth suppression in children (small effect, ~0.5 cm/year)
Contraindications
Known hypersensitivity to budesonide or any component1,2
Primary treatment of acute asthma attacks or status asthmaticus2,3
Active or quiescent pulmonary tuberculosis
Untreated systemic fungal, bacterial, viral, or parasitic infections
Schisandra extract inhibits CYP3A in human pharmacokinetic studies. Budesonide is normally cleared extensively by CYP3A, so inhibition can raise systemic steroid exposure even when budesonide is inhaled, especially at higher doses or with prolonged use.
Recommendation: Avoid adding high-dose Schisandra to inhaled budesonide without clinician review. Monitor for unusual steroid effects such as easy bruising, facial swelling, high glucose, or symptoms of adrenal suppression, but do not stop the inhaled steroid abruptly.
St. John's Wort induces CYP3A4, and budesonide is extensively metabolized by CYP3A. This may lower budesonide exposure and weaken asthma or airway inflammation control, particularly with high-hyperforin St. John's Wort products.
Recommendation: Avoid starting St. John's Wort without discussing asthma or COPD control if you use inhaled budesonide. If the supplement is used anyway, track rescue inhaler use, symptoms, and exacerbations, and do not stop budesonide abruptly.
Zhao J, Pan X, Shao P. Meta-analysis of combined azithromycin and inhaled budesonide treatment for Chinese pediatric patients with mycoplasma pneumonia. Medicine. 2024
Zhu X, Liu Y, Li N et al.. Inhaled budesonide for the prevention of acute mountain sickness: A meta-analysis of randomized controlled trials. The American journal of emergency medicine. 2020
Masoli M, Holt S, Weatherall M et al.. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. The European respiratory journal. 2004
Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC et al.. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial. Annals of internal medicine. 2023
Elfarargy MS, Al-Ashmawy GM, Abu-Risha SM et al.. Inhaled Budesonide in Neonatal Respiratory Distress Syndrome of Near-Term Neonates: A Randomized, Placebo-Controlled Trial. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2022
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Budesonide Inhaled in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack